Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis

Table 3 Clinical characteristics, response to treatment, survival, treatment duration and hospitalization time after first relapse/progression divided by treatment groups (n = 54)

Treatment group	No. of patients	Median age	Response to treatment	Median OS (months)	Median treatment duration (days)	Median hospitalization time (days)	Median KPS at relapse/ progression	Median KPS after treatment^d
TMZ-based ^a (n = 15 TMZ monotherapy, n = 6 TMZ + rituximab)	21	73	CR/CRu n = 4 PR n = 1 PD n = 13 Early death n = 3	4.8	38	15	60	50
HD-MTX-based ^{b c} (n = 8 HD-MTX + TMZ, n = 2 HD-MTX monotherapy, n = 1 HD-MTX + ifosfamide)	11	72	CR/CRu n = 5 PR n = 1 PD n = 4 Early death n = 1	5.8	97	55	60	60
WBRT/ focal radiotherapy	11	72	CR/CRu n = 5 PR n = 1 PD n = 5	7.5	40	13	60	50
Other treatment at cerebral relapse (n = 1 temsirolimus [24], n = 1 rituximab monotherapy)	2	74	PD n = 2	2.1/7.0	27	27	60	40
Best supportive care	9	77	Not applicable	0.8	0	7	50	-

^a 15 of 21 patients were able to be discharged from the hospital and receive treatment at home
^b one of these patients received WBRT after infectious complications and only PR after four cycles of HD-MTX monotherapy and one patient received consolidating local radiotherapy
^c median time from last day of prior treatment to diagnosis of relapse was 22.4 months (range 3.8–83.5 months) in this group
^d patients with treatment related death were not assessable for this analysis
Abbreviations: CR = complete remission, HD-MTX = high dose methotrexate, KPS = Karnofsky performance score, PD = progressive disease, PR = partial remission, RT = radiotherapy, TMZ = temozolomide, WBRT = whole brain radiotherapy

ISSN: 2524-3489